XNYS · ANRO
+2.17% · +$0.5100 · Vol 409.8K
After hours · updated 18:30:00 ET
Alto Neuroscience Inc.

Alto Neuroscience Inc.

PHARMACEUTICAL PREPARATIONS
$24.03
Card
Relationship Map

Follow $ANRO

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $ANRO by email

Veridion Score

BETALOW CONF · 5 of 6 factors measuredMethodology

snapshot unavailable for ANRO. Cause unavailable.

Sentiment absence reason unknown
ANRO
Alto Neuroscience Inc.
Stale score · Wed Oct 7 · completed session · 21h old · Scheduled each trading day · Markets closed · resumes Fri 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100
Veridion Score
Middle range · LOW confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 5 of 6 factors measured · Stale score · Wed Oct 7 · completed session · 21h old · Scheduled each trading day · Markets closed · resumes Fri 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ANRO moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ANRO catalysts
About Alto Neuroscience Inc.
PHARMACEUTICAL PREPARATIONS
Listed since
2024
Employees
68
Country
US

Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$23.03
Day high
$24.05
Day low
$22.81
Previous close
$23.52
52W high
$36.64
-34.42% from high
52W low
$5.62
59% of range
Market cap
$923M
EPS
$-2.5300
Beta
1.50
Shares out
39.2M
Volume
409.8K
0.72× rel vol
Avg volume
566.2K
VWAP
$23.73
Price history computed in-house
1W
-5.06%
1M
-32.90%
3M
-9.25%
1Y
+286.96%
YTD
+35.00%
SMA 50 $30.63 · below
SMA 200 $23.82 · above
52W position 59%

ANRO overview

Veridion Score
59
Registered · 2026-10-07
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around ANRO.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading ANRO Form 4 filings
Public disclosures

Congress activity in ANRO

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

ANRO contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ANRO in this window.
Lobbying spend

ANRO lobbying filings, year to date.

Registered lobbying filings matched to Alto Neuroscience Inc..

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ANRO in this window.
Loading news for ANRO
Analyst ratings
Sovereign unlock shows live analyst consensus for ANRO.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.